<p>PATIENT CONSENT FORM</p>

**Purpose of the test:**

The purpose of the Panorama™ Non-Invasive Prenatal Test (NIPT) is to screen the fetus for the chromosome abnormalities listed in the table below. You have the option of requesting a screen and reporting of the fetal sex as well. Panorama is performed on a maternal blood sample which contains DNA (genetic material) from both the mother and fetus. The fetal DNA tested comes from the placenta; this DNA is identical to the DNA found in the actual cells of the fetus in about 98% of all pregnancies. Panorama is available for women who are at least 9 weeks pregnant. Your health care provider can provide you with more details about the chromosome abnormalities screened with this test.

**Chromosome abnormalities evaluated with Panorama™:**

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trisomy 21</td>
<td>This is caused by an extra copy of chromosome 21 and is also called Down syndrome. This is the most common genetic cause of intellectual disability and occurs in about 1 in every 800 liveborn babies&lt;sup&gt;1&lt;/sup&gt;. Individuals with Down syndrome have an average IQ of 50 and all have some degree of intellectual disability. Some children with Down syndrome have defects of the heart or other organs that may require surgery or medical treatment. Some have other medical conditions including hearing or vision loss.</td>
</tr>
<tr>
<td>Trisomy 18</td>
<td>This is caused by an extra copy of chromosome 18 and is also called Edwards syndrome. Trisomy 18 occurs in about 1 in every 7500 liveborn babies and causes severe intellectual disability&lt;sup&gt;1&lt;/sup&gt;. Most babies with Trisomy 18 have multiple severe birth defects of the brain, heart and other organs. Poor growth during pregnancy is common and many babies are miscarried or stillborn. Of those babies born alive, most die before one year of age. Babies who survive have profound intellectual disabilities and growth and development problems.</td>
</tr>
<tr>
<td>Trisomy 13</td>
<td>This is caused by an extra copy of chromosome 13 and is also called Patau syndrome. Trisomy 13 occurs in about 1 in every 22,700 liveborn babies and causes severe intellectual disability&lt;sup&gt;1&lt;/sup&gt;. Most babies with trisomy 13 have multiple severe birth defects of the brain and other organs. Many babies are miscarried or stillborn. Of those babies born alive, most die before one year of age.</td>
</tr>
<tr>
<td>Monosomy X</td>
<td>This is caused by a missing copy of the X chromosome and is also called Turner syndrome. This only affects girls and is found in about 1 in every 1 in 5000 liveborn babies&lt;sup&gt;1&lt;/sup&gt;. Girls with Monosomy X are shorter than average. Some girls have heart or kidney defects, hearing problems, and some have minor learning disabilities. Girls with Monosomy X may need sex hormone treatments in early childhood and usually need sex hormone treatments at the time of puberty. As adults, they often have infertility.</td>
</tr>
<tr>
<td>Triploidy</td>
<td>This is caused by an extra copy of all chromosomes. Abnormalities are often present in both the placenta and the fetus. It is found in about 1 in 1000 first trimester pregnancies&lt;sup&gt;1&lt;/sup&gt;; most babies with triploidy are miscarried or stillborn. Of those rare babies born alive, most die before one year of age. Mothers carrying a fetus with triploidy can also experience various pregnancy complications such as preeclampsia, severe nausea, excessive bleeding, and placental disease.</td>
</tr>
</tbody>
</table>


**Methods**

Two tubes of blood are required from the mother (16-20cc). The samples are screened for only those chromosome abnormalities listed above (and some microdeletion if chosen)

**Test Results Follow-up:**

A ‘low risk’ result indicates a reduced chance that your fetus has the listed chromosome abnormalities but it cannot guarantee normal chromosomes or a healthy baby.

A ‘high risk’ result indicates that there is an increased likelihood your fetus has one of the chromosome abnormalities tested but does not confirm that the fetus has that abnormality. The recommended follow-up is a prenatal diagnostic test such as chorionic villus sampling (CVS) or amniocentesis. Your health care provider will explain the test results and recommended follow-up steps to you, which may include a referral to a genetic counselor in addition to the prenatal diagnostic testing.

The Panorama screen is not a diagnostic test – it will not confirm any of these chromosome abnormalities. It will only provide the risk for each of these in your current pregnancy. Therefore, DECISIONS ABOUT YOUR PREGNANCY SHOULD NEVER BE MADE BASED ON THESE SCREENING RESULTS ALONE AS THEY NEITHER CONFIRM NOR RULE OUT THE PRESENCE OF A CHROMOSOME ABNORMALITY IN THE FETUS. Follow-up diagnostic testing should always be performed during pregnancy or at birth to confirm or rule out a chromosome abnormality or microdeletion.

There is a chance that the sample(s) submitted will not return results; in this case, a second sample from the mother may be requested to repeat the test at no charge. In rare cases, Natera may not be able to return results on a subsequent sample.
Test Limitation:

Although this screening test will detect the majority of pregnancies in which the fetus has one of the above listed chromosome abnormalities, it cannot detect 100% of pregnancies with these conditions. The results of this test do not eliminate the possibility of other abnormalities of the tested chromosomes, and it does not detect abnormalities of untested chromosomes, other microdeletions, genetic disorders, birth defects, or other complications in your fetus. The Panorama prenatal test was developed by Natera, Inc., a laboratory certified under the U.S. Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Inaccurate test results or a failure to obtain test results may occur due to one or more of the following rare occurrences: courier/shipping delay; sample mixup; laboratory failure or error; biological factors such as but not limited to: sample contamination or degradation, too little DNA from the fetus in the maternal blood sample, mosaicism (a mixture of cells with normal and abnormal chromosomes) in the fetus, placenta or mother, other genetic variants in the mother or fetus, or an unrecognized twin pregnancy; other circumstances beyond our control; or unforeseen problems that may arise. About 1 to 2% of all pregnancies have confined placental mosaicism, a situation in which the placenta has cells with a chromosome abnormality while the fetus has normal chromosomes or vice versa. This means that there is a chance that the chromosomes in the fetus may not match the chromosomes in the DNA screened leading to inaccurate results.

This test cannot be performed on multiple gestation pregnancies (triplets/quadruplets) or pregnancies in which the mother has had a prior bone marrow transplant. If you and your partner are related by blood (e.g. cousins), or if the mother of the pregnancy has parents who are related to each other by blood (e.g., first cousins), the laboratory technology may not be able to return results on your pregnancy. Other testing methods may be a better option for couples with close blood relationships.

Alternatives:

There are multiple other screening options available during pregnancy which can be discussed with your health care provider. You also have the option to decline all chromosome screening tests during your pregnancy. If you want or need conclusive information about the fetal chromosomes, invasive diagnostic tests such as CVS or amniocentesis are available.

Confidential Reporting Practices:

The laboratory complies under the Health Insurance Portability and Accountability Act (HIPAA). Test results will be reported only to the ordering health care provider(s), partner laboratory and/or genetic counselor (where allowed). You must contact your provider to obtain the results of the test. Additionally, the test results could be released to those who, by law, may have access to such data.

Financial Responsibilities:

You are responsible for all costs related to the Panorama NPT. If the result shows as high risk for panel that you have chosen, the laboratory will support the cost of confirming the results on the amniotic fluid diagnostic test at the actual cost or in the amount of up to 10,000 baht. If the result shows as low risk, however, the baby is born alive and diagnosed with Trisomy 21, Trisomy 18 or Trisomy 13, The company has been insured against Medical Malpractice for up to a maximum of 3,500,000 Baht. The company needs to be informed within one year from the date of report delivery together with diagnostic report and document that must be obtained from a certified laboratory.

Disposition or Retention of samples:

The laboratory may also keep your leftover de-identified samples for ongoing research and development. You and your heirs will not receive any payments, benefits, or rights to any resulting products or discoveries. If you do not want your de-identified sample used, you may send a request in writing to Bangkok Cytogenetics Center at Attn: Sample Retention, 65/18 Soi. Vibhavadi-Rangsit 16/6, Vibhavadi-Rangsit rd., Chom Phon, Chatuchak, Bangkok 10900 within 60 days after test results have been issued and your sample will be destroyed.

Patient Consent statement:

I have read or have had read to me the above informed consent information about the Panorama Non-Invasive Prenatal Test (NIPT). I have had the opportunity to ask questions of my health care provider regarding this test, including the reliability of test results, the risks, and the alternatives prior to my informed consent. I request and authorize the laboratory to test my sample(s) for the chromosome abnormalities listed above. I acknowledge that I must sign the consent statement located on the test requisition form that will be sent with my sample(s) to the laboratory. I understand that I must also sign this consent form which will be sent together with the sample.

(  )  
Signature of patient  
(  )  
Date